Oncotelic Therapeutics Net Profit Margin Growth & History (OTLC)
Oncotelic Therapeutics's net profit margin was −11,290.13% for fiscal 2023.
View full Oncotelic Therapeutics company overviewOncotelic Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −11,290.13% | — |
| 2020 | 2020-12-31 | −545.86% | — |
| 2013 | 2013-12-31 | −8,712.63% | −3533.79 pp |
| 2012 | 2012-12-31 | −5,178.85% | — |
Oncotelic Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 155.26% | — |
| Q3 2023 | 2023-09-30 | 164.73% | — |
| Q2 2020 | 2020-06-30 | 41.58% | — |
| Q1 2020 | 2020-03-31 | −1,366.53% | — |
| Q3 2013 | 2013-09-30 | −2,785.26% | — |
| Q4 2012 | 2012-12-31 | −3,988.10% | — |
| Q1 2012 | 2012-03-31 | −1,658.77% | — |
Oncotelic Therapeutics net profit margin trends
Between the periods ended 2012-12-31 and 2023-12-31, Oncotelic Therapeutics's net profit margin decreased from −5,178.85% to −11,290.13%, a change of −6111.29 percentage points. The latest reported quarter, Q2 2026, shows 155.26%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oncotelic Therapeutics source filings ↗